Chronic Kidney Disease
Hemoglobin glycation index may predict CKD risk in diabetes
A high hemoglobin glycation index is associated with an increased risk for incident chronic kidney disease during 10 years of follow-up among treatment-naive adults with prediabetes or type 2 diabetes, according to a speaker.
Common hypertension drug linked to increased need for dialysis in patients with CKD
Use of alpha-blockers – commonly prescribed to treat hypertension – was associated with eGFR decline in patients with chronic kidney disease, leading to an increased need for dialysis or transplantation.
Symptom burden in CKD stages 3 to 5 is ‘pervasive’
Understanding symptom clusters could help practitioners manage the symptoms of chronic kidney disease, researchers said in a poster presented at the American Nephrology Nurses Association National Symposium.
Belimumab plus standard therapy superior to standard therapy alone for lupus nephritis
A 2-year randomized controlled trial has found that belimumab plus standard therapy is superior to standard therapy alone in patients with lupus nephritis, according to data published in the New England Journal of Medicine.
Researchers identify modifiable lifestyle factors to prevent CKD, including diet changes
Researchers from Australia have identified several modifiable factors associated with the likelihood of study participants developing chronic kidney disease.
Equations converting urine PCR and dipstick protein measures to ACR helpful in staging CKD
Measuring albuminuria in urine is the gold standard for defining and staging chronic kidney disease, or CKD, according to researchers.
Patient resources for low-potassium diets ‘likely’ need update to reflect guidelines
After reviewing patient resources on low-potassium diets for the management of hyperkalemia in chronic kidney disease, researchers from Canada suggested updates be made as the current information fails to address new expert recommendations.
Dapagliflozin cuts renal, CV events in CKD, regardless of diabetes status
In the DAPA-CKD trial, treatment with the SGLT2 inhibitor dapagliflozin reduced risk for worsening renal function and death due to CVD or renal disease in patients with chronic kidney disease, both with and without type 2 diabetes.
Hyperkalemia prevalent, increases health care costs for older adults
More than 2% of the U.S. Medicare population has hyperkalemia, with a higher prevalence among adults with chronic kidney disease or heart failure, according to a study published in Current Medical Research and Opinion.
Triple combination therapy may be optimal for CV protection in type 2 diabetes
Triple therapy combining an SGLT2 inhibitor, a GLP-1 receptor agonist and the thiazolidinedione pioglitazone could serve as an optimal solution for cardiovascular and renal protection in type 2 diabetes, according to a speaker.